144 related articles for article (PubMed ID: 3078949)
21. The c-myc promoter: still MysterY and challenge.
Wierstra I; Alves J
Adv Cancer Res; 2008; 99():113-333. PubMed ID: 18037408
[TBL] [Abstract][Full Text] [Related]
22. Regulation of c-fgr proto-oncogene expression in Burkitt's lymphoma cells: effect of interferon treatment and relationship to EBV status and c-myc mRNA levels.
Sharp NA; Luscombe MJ; Clemens MJ
Oncogene; 1989 Aug; 4(8):1043-6. PubMed ID: 2548145
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of the translocated c-myc in Burkitt's lymphoma by a PNA complementary to the E mu enhancer.
Cutrona G; Carpaneto EM; Ponzanelli A; Ulivi M; Millo E; Scarfì S; Roncella S; Benatti U; Boffa LC; Ferrarini M
Cancer Res; 2003 Oct; 63(19):6144-8. PubMed ID: 14559793
[TBL] [Abstract][Full Text] [Related]
24. Mode of c-myc gene regulation in folic acid-induced kidney regeneration.
Asselin C; Marcu KB
Oncogene Res; 1989; 5(1):67-72. PubMed ID: 2476708
[TBL] [Abstract][Full Text] [Related]
25. Iron specific growth inhibition of Burkitt's lymphoma cells in vitro, associated with a decrease in translocated c-myc expression.
Habel ME; Lemieux R; Jung D
J Cell Physiol; 2005 Apr; 203(1):277-85. PubMed ID: 15468060
[TBL] [Abstract][Full Text] [Related]
26. Effects of IL-3 on promoter usage, attenuation and antisense transcription of the c-myc oncogene in the IL-3-dependent Ba/F3 early pre-B cell line.
Chang Y; Spicer DB; Sonenshein GE
Oncogene; 1991 Nov; 6(11):1979-82. PubMed ID: 1682864
[TBL] [Abstract][Full Text] [Related]
27. Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences.
Sandlund JT; Neckers LM; Schneller HE; Woodruff LS; Magrath IT
Cancer Res; 1993 Jan; 53(1):127-32. PubMed ID: 8416737
[TBL] [Abstract][Full Text] [Related]
28. Expression of c-fos and c-myc in Raji Burkitt's lymphoma cells during the progression of DMSO-induced G1 cells into S phase.
Teraoka H; Sawai M; Takase K; Yamamoto K; Nozaki N; Okazaki T; Tsukada K
Exp Cell Res; 1991 Jul; 195(1):274-6. PubMed ID: 1905238
[TBL] [Abstract][Full Text] [Related]
29. Expression of cellular oncogenes: unrearranged c-myc gene but altered promoter usage in radiation-induced thymoma.
Bandyopadhyay SK; D'Andrea E; Fleissner E
Oncogene Res; 1989; 4(4):311-8. PubMed ID: 2475843
[TBL] [Abstract][Full Text] [Related]
30. The in vivo binding site for oncoprotein c-Myc in the promoter for Epstein-Barr virus (EBV) encoding RNA (EBER) 1 suggests a specific role for EBV in lymphomagenesis.
Niller HH; Salamon D; Ilg K; Koroknai A; Banati F; Bauml G; Rucker O; Schwarzmann F; Wolf H; Minarovits J
Med Sci Monit; 2003 Jan; 9(1):HY1-9. PubMed ID: 12552250
[TBL] [Abstract][Full Text] [Related]
31. Transcriptional arrest within the first exon is a fast control mechanism in c-myc gene expression.
Eick D; Bornkamm GW
Nucleic Acids Res; 1986 Nov; 14(21):8331-46. PubMed ID: 3537956
[TBL] [Abstract][Full Text] [Related]
32. Distinct mechanisms of c-myc and lymphokine gene expression in an antigen specific T cell clone.
Heckford SE; Gelmann EP; Matis LA
Oncogene; 1988 Oct; 3(4):415-21. PubMed ID: 3152599
[TBL] [Abstract][Full Text] [Related]
33. In situ and in vitro evidence for intragenic binding of nuclear factors at the murine c-myc locus.
Tourkine N; Mechti N; Piechaczyk M; Jeanteur P; Blanchard JM
Oncogene; 1989 Aug; 4(8):973-8. PubMed ID: 2548146
[TBL] [Abstract][Full Text] [Related]
34. The Epstein-Barr virus BRLF1 gene product transactivates the murine and human c-myc promoters.
Gutsch DE; Marcu KB; Kenney SC
Cell Mol Biol (Noisy-le-grand); 1994 Sep; 40(6):747-60. PubMed ID: 7812182
[TBL] [Abstract][Full Text] [Related]
35. ECA39 is regulated by c-Myc in human and by a Jun/Fos homolog, Gcn4, in yeast.
Ben-Yosef T; Yanuka O; Benvenisty N
Oncogene; 1996 Nov; 13(9):1859-66. PubMed ID: 8934531
[TBL] [Abstract][Full Text] [Related]
36. Expression of normal and translocated c-myc alleles in Burkitt's lymphoma cells: evidence for different regulation.
Eick D; Bornkamm GW
EMBO J; 1989 Jul; 8(7):1965-72. PubMed ID: 2551669
[TBL] [Abstract][Full Text] [Related]
37. Decreased steady state c-myc mRNA in activated T cell cultures from old humans is caused by a smaller proportion of T cells that transcribe the c-myc gene.
Gamble DA; Schwab R; Weksler ME; Szabo P
J Immunol; 1990 May; 144(9):3569-73. PubMed ID: 2184192
[TBL] [Abstract][Full Text] [Related]
38. Expression of a transfected human c-myc oncogene inhibits differentiation of a mouse erythroleukaemia cell line.
Dmitrovsky E; Kuehl WM; Hollis GF; Kirsch IR; Bender TP; Segal S
Nature; 1986 Aug 21-27; 322(6081):748-50. PubMed ID: 3528861
[TBL] [Abstract][Full Text] [Related]
39. c-myc Suppression in Burkitt's lymphoma cells.
Simonsson T; Henriksson M
Biochem Biophys Res Commun; 2002 Jan; 290(1):11-5. PubMed ID: 11779125
[TBL] [Abstract][Full Text] [Related]
40. Loss of transcriptional attenuation in N-myc is associated with progression towards a more malignant phenotype.
Xu L; Meng Y; Wallen R; DePinho RA
Oncogene; 1995 Nov; 11(9):1865-72. PubMed ID: 7478616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
